ResearchNutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy
Section snippets
Ethical considerations
The investigators obtained approval of the study and consent form from the Institutional Review Board at the participating clinics or hospitals. Parents of all children signed informed consent forms.
Study design
A one-year study was conducted longitudinally in children with PKU (2.0 to 12.2 years of age) undergoing therapy with a medical food. Nutrient intake, physical growth, and plasma amino acid concentrations were assessed in 58 children. The study began in March 1996 and ended December 1999. Nine sites participated in the study.
Subject selection criteria
Children meeting the following criteria were eligible for study: diagnosed as having classical PKU and treatment initiated within the first month of life; free of major
Subjects
Twenty-seven Phenex-fed, 18 Periflex-fed, and 22 Phenyl-Free-fed children enrolled in the study. Data of 3 Phenex-fed, 4 Periflex-fed, and 2 Phenyl-Free-fed children are excluded from this report because of failure to attend clinic appointments (n=6), blood samples not obtained according to protocol (n=1), child consuming two different medical foods simultaneously (n=1), and one subject being placed on MVI. Mean±SEM ages of children at study entrance were Phenex-fed 5.0±0.5 years, Periflex-fed
Medical food and nutrient intakes
Phenex-fed children had a lower mean intake of medical food than the Periflex-fed and the Phenyl-Free-fed groups. This lower intake of medical food was related to the greater protein equivalent content of Phenex-2 (30 g/100 g) compared to that of Periflex and Phenyl-Free (20 g/100 g each). The younger age of the Phenex-fed group may also have been partially responsible for the differences in intake.
Mean energy intakes of the three groups of children, as a percentage of RDI, did not differ. Mean
Applications
Nutrient intakes of children with PKU met or exceeded RDIs when protocol-recommended protein intakes were ingested, suggesting that protein intakes were adequate when a major portion was obtained from an elemental medical food, indicating that dietitians should prescribe and encourage protein intakes greater than RDIs. Linear growth of children with PKU was within the normal range; however, obesity was present in a significant number of children, suggesting the need for dietitians to plot
Acknowledgements
The authors thank Mary Jane Kennedy, RN, and US Public Health Service grant No. M01-RR00039 for the General Clinical Research Center at Emory University School of Medicine, Atlanta, GA, for help with recruitment. This research was supported by Ross Products Division, Abbott Laboratories, Columbus, OH.
P. B. Acosta is Director, Metabolic Diseases, with Ross Products Division, Abbott Laboratories, Columbus, OH.
References (32)
- et al.
Nutrient intake of treated infants with phenylketonuria
Am J Clin Nutr
(1977) - et al.
Phenylalanine intakes of 1-to-6-year-old children with phenylketonuria undergoing therapy
Am J Clin Nutr
(1983) Phenylalanine deficiency syndrome
J Pediatr
(1966)- et al.
New England maternal PKU projectprospective study of untreated and treated pregnancies and their outcomes
J Pediatr
(1987) - et al.
Physical growthNational Center for Health Statistics percentiles
Am J Clin Nutr
(1979) - et al.
Resting energy expenditures in children with phenylketonuria
Am J Clin Nutr
(1995) - et al.
Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients
Am J Clin Nutr
(2000) - et al.
Twelve years of clinical experience with phenylketonuriaa statistical evaluation of symptoms, growth, mental development, electroencephalic records, serum phenylalanine levels, and results of dietary management
Neurology
(1969) - et al.
Malnutrition with early treatment of phenylketonuria
Pediatr Res
(1970) - et al.
The depressing effect of diet on physical growth in phenylketonuria
Dev Med Child Neurol
(1971)
Physical growth in phenylketonuria: II. Growth of treated children in the PKU Collaborative Study from birth to 4 years of age
Pediatrics
Intellectual assessment of 111 four-year old children with phenylketonuria
Pediatrics
Growth and skeletal maturation in children with phenylketonuria
Acta Paediatr
Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria
Arch Dis Child
Growth in patients with phenylketonuria
Eur J Pediatr
Physical growth in patients with phenylketonuria
J Inherit Metab Dis
Cited by (72)
Evaluation of the effect of obesity, dietary glycemic index and metabolic profiles on the cardiovascular risk in children with classical phenylketonuria
2023, Molecular Genetics and MetabolismInborn errors of metabolism: Nutrition management of phenylketonuria
2023, Encyclopedia of Human Nutrition: Volume 1-4, Fourth EditionPreformulation Studies with Phenylalanine Ammonia Lyase: Essential Prelude to a Microcapsule Formulation for the Management of Phenylketonuria
2022, Journal of Pharmaceutical SciencesOverweight/obesity in adolescents with phenylketonuria: protective and predisposing factors
2022, Jornal de PediatriaCarriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria
2020, Molecular Genetics and Metabolism ReportsNutraceutical Food: Composition, Biosynthesis, Therapeutic Properties, and Applications
2018, Alternative and Replacement Foods
P. B. Acosta is Director, Metabolic Diseases, with Ross Products Division, Abbott Laboratories, Columbus, OH.
S. Yannicelli is Director, Education, with Pharmavite, Northridge, CA. At the time the study was conducted, he was with Ross Products Division, Abbott Laboratories, Columbus, OH.
R. Singh is Director, Nutrition, with the Division of Medical Genetics, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
S. Mofidi is a metabolic dietitian with the Department of Pediatric Allergy, Mt Sinai Medical Center, New York, NY. At the time the study was conducted, she was with the Children’s Hospital of Los Angeles, Los Angeles, CA.
R. Steiner is Chief of the Division of Metabolism, Departments of Pediatrics and Molecular and Medical Genetics, Oregon Health Sciences University, Portland, OR.
E. DeVincentis is a metabolic dietitian with the Division of Genetics, Children’s Hospital, Buffalo, NY.
E. Jurecki is a metabolic dietitian with the Regional Metabolic Center, Kaiser Permanente Medical Center, Oakland, CA.
L. Bernstein is a metabolic dietitian with the Inherited Metabolic Disease Clinic, The Children’s Hospital, Denver, CO.
S. Gleason is a metabolic dietitian with the Metabolic Center, University of Wisconsin, Madison.
M. Chetty is a metabolic dietitian with Regional Metabolic Services, Kaiser Foundation Hospital, Los Angeles, CA.
B. Rouse is Director, Child Development, with the Department of Pediatrics, University of Texas Medical Branch, Galveston.